NCT06860633View on ClinicalTrials.gov

Treatment of Myasthenia Gravis Exacerbation or Crisis With Efgartigimod

PHASE4RecruitingINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

March 6, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Myasthenia Gravis CrisisMyasthenia Gravis ExacerbationsAChR Myasthenia Gravis

Interventions

DRUG

Efgartigimod

Dose of 10 mg/kg for IV infusion on days 1, 4, 11 and 18

Trial Locations (1)

80045

RECRUITING

University of Colorado, Aurora

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

argenx

INDUSTRY

lead

University of Colorado, Denver

OTHER

NCT06860633 - Treatment of Myasthenia Gravis Exacerbation or Crisis With Efgartigimod | Biotech Hunter | Biotech Hunter